The clinical study I was involved in was the first of its kind in the UK, examining psilocybin's effects on 20 people with treatment-resistant depression.

Participants often report that the psilocybin sessions felt more human and connected compared to traditional treatments, emphasizing the importance of the therapeutic relationship. Seventeen out of twenty participants experienced significant improvements in their depression after a single psilocybin session, feeling better for months, but many saw their symptoms return after three months.

This research project on psilocybin started after various studies explored its effects on the brain, particularly focusing on the unconscious mind and how it influences behavior.

For some participants, the effects of psilocybin lasted for about two to three months before their depression began to return, highlighting the need for integration after the experience.

It's incredibly challenging to tell participants that we can't provide them with follow-up sessions due to funding constraints, especially when they've experienced such profound relief from their depression.

The therapeutic bond developed during psilocybin sessions is different from traditional therapy, as it fosters a more human and equal relationship between participants and guides.

Psychedelics like psilocybin have shown promising results in reducing alcohol consumption by increasing neuroplasticity and forming new brain pathways.

I'm surprised we haven't made faster progress in using psychedelics for mental health, but I'm still optimistic about it.

Psychedelics like ibogaine and psilocybin show promise in treating addiction, but ethical considerations and proper therapeutic support are essential for their use.